Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of targeted therapies for patients with specific biomarkers has begun to fragment the NSCLC treatment landscape into smaller niche patient populations. Over the forecast period, this trend will continue with the launch of multiple new drugs in several new drug classes to address the high unmet need among NSCLC patients, and provide new treatment options for previously underserved populations.

This Event-Driven Update was published in response to major events that occurred during the first quarter of 2014 that will result in the failure of several premium-priced agents to launch in the US and global markets during the forecast period. These agents include Pfizer’s dacomitinib and Boehringer Ingelheim’s nintedanib in the US, and Roche’s MetMab (onartuzumab) and GSK’s MAGE-A3 immunotherapy in the global markets.

Highlights

Key Questions Answered

• The NSCLC market will become increasingly crowded during the forecast. How will the first and second lines of therapy be impacted by the launch of new therapies?
• How will the failure of dacomitinib and nintedanib to launch in the US affect global market growth? What effect will the failure to launch of MetMab (onartuzumab) and the MAGE-A3 immunotherapy in the nine major markets have on global market dynamics?
• How will the increasing stratification of patient populations by biomarkers affect the treatment landscape?
• The unmet needs of NSCLC patients are relatively high. What unmet needs will be addressed by the launch of new treatment options during the forecast period? What unmet needs will remain?
• How will Alimta, Avastin, Iressa and Tarceva patent expirations affect overall market growth during the forecast?
• How will increasing cost consciousness among European reimbursement authorities affect market growth in the 5EU?

Key Findings

• Launch of emerging pipeline therapies will result in more patients receiving premium-priced drugs in the first and second lines of therapy, and market growth in the US and Japan. However, the US and nine major markets will be negatively affected by the failure of premium-priced agents including dacomitinib, nintedanib, MetMab and MAGE-A3 to launch during the forecast period.
• Despite the launch of remaining premium-priced therapies such as Eli Lilly’s necitumumab and BMS’ nivolumab, the NSCLC market will shrink in the 5EU. This will be primarily due to the reduction in number of new premium-priced agents that will launch as well as the loss of patent protection for most of the major branded therapies as well as increasing cost pressures from European reimbursement authorities.
• The Indian and Chinese markets will continue to be difficult to penetrate. Many emerging pipeline therapies will not launch in these markets, especially expensive biologic therapies. Generic competition, regulatory hurdles and high cost of therapies will be major barriers to growth in these markets.
• BMS’s nivolumab will emerge as the overall market leader in 2022, launching first in the second-line segment in 2015 and expanding into the first-line segment in 2019. Uptake will be driven by the drug’s promising clinical efficacy in both squamous and non-squamous patients and strong safety profile.
• After Iressa and Tarceva lose patent protection in 2019 and 2020, respectively, Boehriger Ingelheim’s Gilotrif (afatinib) will emerge as the leading therapy for EGFR-positive patients. Gilotrif’s market position will be driven by high uptake in the second-line segment.
• Pfizer’s Xalkori will lose ALK-positive patient share to Novartis’ ceritinib (LDK378) in the second-line segment. However, Xalkori will continue to be the patient share leader in the more lucrative first line setting and will maintain the overall sales leadership over LDK378 throughout the forecast.

Scope

• Overview of NSCLC, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
• Annualized NSCLC therapeutics market revenue, annual cost of therapy and treatment usage pattern data by patient segment forecast from 2012 to 2022.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the NSCLC therapeutics market.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for different lines of therapy. The most promising 13 candidates in Phase III development are profiled.
• Analysis of the current and future market competition in the global NSCLC market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

• Develop business strategies by understanding the trends shaping and driving the global NSCLC therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global NSCLC therapeutics market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Forecast drug sales in the global NSCLC therapeutics market from 2012-2022.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies.

Table of Contents

1 Table of Contents 9
1.1 List of Tables 16
1.2 List of Figures 22

2 Introduction 24
2.1 Catalyst 24
2.2 Related Reports 25
2.3 Upcoming Related Reports 25

3 Disease Overview 26
3.1 Etiology and Pathophysiology 26
3.1.1 Etiology 26
3.1.2 Pathophysiology and Histology 26
3.1.3 NSCLC Biomarkers 27
3.1.4 Quality of Life 28
3.2 Symptoms 29

4 Epidemiology 31
4.1 Risk Factors and Comorbidities 32
4.1.1 Smokers are more likely to have lung cancer than non-smokers 33
4.1.2 Long-term exposure to radon increases the risk of lung cancer 35
4.1.3 Family history of any cancer increases lung cancer risk 35
4.1.4 TB increases the risk of lung cancer and increases mortality risk 35
4.1.5 COPD is a comorbidity that reduces lung cancer survival 36
4.1.6 Lung cancer screening programs may not be beneficial 36
4.1.7 Stage at diagnosis significantly impacts the survival of lung cancer cases 37
4.2 Global Trends 38
4.2.1 US 41
4.2.2 France 46
4.2.3 Germany 47
4.2.4 Italy 49
4.2.5 Spain 51
4.2.6 UK 53
4.2.7 Japan 54
4.2.8 China 56
4.2.9 India 58
4.3 Forecast Methodology 60
4.3.1 Sources Used 62
4.3.2 Sources Not Used 67
4.3.3 Forecast Assumptions and Methods 67
4.4 Epidemiology Forecast (2012-2022) 70
4.4.1 Incident/Prevalent Cases of NSCLC 70
4.4.2 Age-Specific Incident Cases of NSCLC 72
4.4.3 Sex-Specific Incident Cases of NSCLC 73
4.4.4 Age-Standardized Incidence Rates of NSCLC 75
4.4.5 Segmentation of NSCLC Incident Cases 76
4.5 Discussion 84
4.5.1 Limitations of the Analysis 85
4.5.2 Strengths of the Analysis 86

5 Disease Management 87
5.1 Treatment Overview 87
5.1.1 Diagnosis 88
5.1.2 Clinical Staging 89
5.1.3 Screening and Early Detection 91
5.1.4 Localized Procedures and Therapies 92
5.1.5 Systemic Chemotherapy 93
5.1.6 Targeted Therapy 93
5.2 US 96
5.2.1 Diagnosis 96
5.2.2 Clinical Practice 96
5.3 France 98
5.3.1 Diagnosis 98
5.3.2 Clinical Practice 99
5.4 Germany 100
5.4.1 Diagnosis 100
5.4.2 Clinical Practice 101
5.5 Italy 103
5.5.1 Diagnosis 103
5.5.2 Clinical Practice 104
5.6 Spain 105
5.6.1 Diagnosis 105
5.6.2 Clinical Practice 105
5.7 UK 106
5.7.1 Diagnosis 106
5.7.2 Clinical Practice 107
5.8 Japan 108
5.8.1 Diagnosis 108
5.8.2 Clinical Practice 109
5.9 China 110
5.9.1 Diagnosis 110
5.9.2 Clinical Practice 111
5.10 India 112
5.10.1 Diagnosis 112
5.10.2 Clinical Practice 112

6 Competitive Assessment 115
6.1 Overview 115
6.2 Strategic Competitor Assessment 116
6.3 Product Profiles - Major Brands, Chemotherapies 118
6.3.1 Alimta (pemetrexed disodium) 118
6.3.2 Abraxane (nab-paclitaxel) 123
6.4 Product Profiles - Major Brands, Targeted Therapies 127
6.4.1 Avastin (bevacizumab) 127
6.4.2 Gilotrif (afatinib) 132
6.4.3 Iressa (gefitinib) 138
6.4.4 Tarceva (erlotinib hydrochloride) 143
6.4.5 Xalkori (crizotinib) 149

7 Opportunity and Unmet Need 156
7.1 Overview 156
7.2 Improved Overall Survival and Less Toxicity 157
7.3 Treatments for Patients with Acquired TKI Resistance 158
7.4 Better Treatment Options for Squamous Patients 158
7.5 Preventing Relapse or Recurrence 159
7.6 More Efficacious Second-Line Therapies 159
7.7 Increased Availability of Mutation Testing 160
7.8 More Cost-Effective Therapies 160
7.9 Unmet Needs Gap Analysis 161

8 Pipeline Assessment 165
8.1 Overview 165
8.2 Clinical Trial Mapping 165
8.2.1 Clinical Trials by Country 165
8.3 Clinical Trials by Phase and Trial Status 167
8.4 Promising Drugs in Clinical Development 168
8.4.1 Onartuzumab (MetMab) 172
8.4.2 Necitumumab (IMC-11F8) 177
8.4.3 Ramucirumab (IMC-1121B) 183
8.4.4 Custirsen (OGX-011) 188
8.4.5 Ganetespib (STA-9090) 194
8.4.6 Nintedanib (BIBF1120) 201
8.4.7 Dacomitinib (PF-00299804) 206
8.4.8 LDK378 (ceritinib) 211
8.4.9 Yervoy (ipilimumab) 217
8.4.10 Nivolumab (BMS936558) 222
8.4.11 MPDL3280A (RG7446) 230
8.4.12 GSK1572932A (MAGE-A3 Cancer Immunotherapy) 233
8.4.13 Halaven (eribulin mesylate) 237

9 Current and Future Players 243
9.1 Overview 243
9.2 Trends in Corporate Strategy 245
9.3 Company Profiles 246
9.3.1 Roche/Genentech 246
9.3.2 Pfizer 249
9.3.3 Bristol-Myers Squibb 251
9.3.4 Eli Lilly 254
9.3.5 Boehringer Ingelheim 257
9.3.6 Novartis 259

10 Market Outlook 261
10.1 Global Markets 261
10.1.1 Forecast 261
10.1.2 Drivers and Barriers - Global Issues 265
10.2 United States 269
10.2.1 Forecast 269
10.2.2 Key Events 273
10.2.3 Drivers and Barriers 274
10.3 France 277
10.3.1 Forecast 277
10.3.2 Key Events 281
10.3.3 Drivers and Barriers 282
10.4 Germany 284
10.4.1 Forecast 284
10.4.2 Key Events 288
10.4.3 Drivers and Barriers 289
10.5 Italy 291
10.5.1 Forecast 291
10.5.2 Key Events 295
10.5.3 Drivers and Barriers 295
10.6 Spain 297
10.6.1 Forecast 297
10.6.2 Key Events 300
10.6.3 Drivers and Barriers 301
10.7 United Kingdom 302
10.7.1 Forecast 302
10.7.2 Key Events 306
10.7.3 Drivers and Barriers 307
10.8 Japan 309
10.8.1 Forecast 309
10.8.2 Key Events 313
10.8.3 Drivers and Barriers 313
10.9 China 316
10.9.1 Forecast 316
10.9.2 Key Events 320
10.9.3 Drivers and Barriers 320
10.10 India 323
10.10.1 Forecast 323
10.10.2 Key Events 327
10.10.3 Drivers and Barriers 327

11 Appendix 329
11.1 Bibliography 329
11.2 Abbreviations 360
11.3 Methodology 365
11.4 Forecasting Methodology 365
11.4.1 Number of NSCLC Patients Currently Seeking Treatment 365
11.4.2 Percent Drug-Treated Patients 366
11.4.3 Drugs Included in Each Therapeutic Class 366
11.4.4 Launch and Patent Expiry Dates 367
11.4.5 General Pricing Assumptions 368
11.4.6 Individual Drug Assumptions 371
11.4.7 Generic Erosion 381
11.4.8 Pricing of Pipeline Agents 381
11.5 Physicians and Specialists Included in This Study 383
11.6 Survey of Prescribing Physicians 385
11.7 About the Authors 386
11.7.1 Authors 386
11.7.2 Epidemiologists 387
11.7.3 Global Head of Healthcare 388
11.8 About GlobalData 389
11.9 Disclaimer 389

List of Tables

Table 1: Symptoms of NSCLC 30
Table 2: Risk Factors and Comorbidities for Lung Cancer 33
Table 3: 9MM, Age-Standardized (World) Smoking Prevalence, Men and Women, 2006 and 2009 40
Table 4: 9MM, Sources of NSCLC Incidence Data 61
Table 5: 9MM, Incident Cases of NSCLC, Men and Women Ages ?40 Years, N, Selected Years 2012-2022 70
Table 6: 9MM, Incident Cases of NSCLC, by Age, Men and Women, N (Row %), 2012 73
Table 7: 9MM, Incident Cases of NSCLC, by Sex, Ages ?40 Years, N (Row %), 2012 74
Table 8: 9MM, Incident Cases of NSCLC, by Stage at Diagnosis, Men and Women Ages ?40 Years, N (Row %), 2012 78
Table 9: 9MM, Incident Cases of NSCLC, by Histological Subtype, Ages ?40 Years, Men and Women, N (Row %) , 2012 81
Table 10: Comparison of GlobalData Forecast for Lung Cancer Incident Cases With Globocan 2008 86
Table 11: Treatment Guidelines for NSCLC 88
Table 12: Stage Definitions for NSCLC 90
Table 13: Treatment Overview by Stage of Diagnosis for NSCLC 95
Table 14: Leading Branded Treatments for NSCLC 118
Table 15: Product Profile - Alimta (pemetrexed disodium) 120
Table 16: Alimta SWOT Analysis, 2013 122
Table 17: Global Sales Forecasts ($m) for Alimta, 2012-2022 123
Table 18: Product Profile - Abraxane (nab-paclitaxel) 124
Table 19: Abraxane SWOT Analysis, 2013 126
Table 20: Global Sales Forecasts ($m) for Abraxane, 2012-2022 127
Table 21: Product Profile - Avastin (bevacizumab) 129
Table 22: Avastin SWOT Analysis, 2013 131
Table 23: Global Sales Forecasts ($m) for Avastin, 2012-2022 132
Table 24: Product Profile - Gilotrif (afatinib) 134
Table 25: Gilotrif SWOT Analysis, 2013 136
Table 26: Global Sales Forecasts ($m) for Gilotrif, 2012-2022 138
Table 27: Product Profile - Iressa (gefitinib) 140
Table 28: Iressa SWOT Analysis, 2013 142
Table 29: Global Sales Forecasts ($m) for Iressa, 2012-2022 143
Table 30: Product Profile - Tarceva (erlotinib hydrochloride) 145
Table 31: Tarceva SWOT Analysis, 2013 148
Table 32: Global Sales Forecasts ($m) for Tarceva, 2012-2022 149
Table 33: Product Profile - Xalkori (crizotinib) 151
Table 34: Xalkori SWOT Analysis, 2013 154
Table 35: Global Sales Forecasts ($m) for Xalkori, 2012-2022 155
Table 36: Overall Unmet Needs - Current Level of Attainment 157
Table 37: Clinical Unmet Needs - Gap Analysis, 2013 162
Table 38: NSCLC - Clinical Trials by Phase and Status, 2013 167
Table 39: NSCLC - Promising Candidates in the Phase I-II Pipeline, 2013 169
Table 40: NSCLC - Phase III Pipeline, 2013 170
Table 41: NSCLC - Advantages and Disadvantages of Therapeutic Drug Classes 171
Table 42: Product Profile - Onartuzumab (MetMab) 173
Table 43: Product Profile - Necitumumab (IMC-11F8) 179
Table 44: Necitumumab SWOT Analysis, 2013 182
Table 45: Global Sales Forecasts ($m) for Necitumumab, 2012-2022 183
Table 46: Product Profile - Ramucirumab (IMC-1121B) 184
Table 47: Ramucirumab SWOT Analysis, 2013 187
Table 48: Global Sales Forecasts ($m) for Ramucirumab, 2012-2022 188
Table 49: Product Profile - Custirsen (OGX-011) 189
Table 50: Custirsen SWOT Analysis, 2013 193
Table 51: Global Sales Forecasts ($m) for Custirsen, 2012-2022 194
Table 52: Product Profile - Ganetespib (STA-9090) 195
Table 53: Ganetespib SWOT Analysis, 2013 200
Table 54: Global Sales Forecasts ($m) for Ganetespib, 2012-2022 201
Table 55: Product Profile - Nintedanib (BIBF-1120) 202
Table 56: Nintedanib SWOT Analysis, 2013 205
Table 57: Global Sales Forecasts ($m) for Nintedanib, 2012-2022 206
Table 58: Product Profile - Dacomitinib (PF-00299804) 207
Table 59: Dacomitinib SWOT Analysis, 2013 210
Table 60: Global Sales Forecasts ($m) for Dacomitinib, 2012-2022 211
Table 61: Product Profile - LDK378 212
Table 62: LDK378 SWOT Analysis, 2013 216
Table 63: Global Sales Forecasts ($m) for LDK378, 2012-2022 217
Table 64: Product Profile - Yervoy (ipilimumab) 218
Table 65: Yervoy SWOT Analysis, 2013 221
Table 66: Global Sales Forecasts ($m) for Yervoy, 2012-2022 222
Table 67: Product Profile - Nivolumab (BMS936558) 223
Table 68: Nivolumab SWOT Analysis, 2013 228
Table 69: Global Sales Forecasts ($) for Nivolumab, 2012-2022 229
Table 70: Product Profile - MPDL3280A (RG7446) 230
Table 71: MPDL3280A SWOT Analysis, 2013 233
Table 72: Product Profile - GSK1572932A (MAGE-A3 Immunotherapy) 235
Table 73: Product Profile - Halaven (eribulin mesylate) 238
Table 74: Halaven SWOT Analysis, 2013 241
Table 75: Global Sales Forecasts ($m) for Halaven, 2012-2022 242
Table 76: Key Companies in the NSCLC Market, 2013 244
Table 77: Roche/Genentech's NSCLC Portfolio Assessment, 2013 248
Table 78: Roche/Genentech SWOT Analysis, 2013 249
Table 79: Pfizer's NSCLC Portfolio Assessment, 2013 250
Table 80: Pfizer SWOT Analysis, 2013 251
Table 81: BMS' NSCLC Portfolio Assessment, 2013 253
Table 82: BMS SWOT Analysis, 2013 254
Table 83: Eli Lilly's NSCLC Portfolio Assessment, 2013 256
Table 84: Eli Lilly SWOT Analysis, 2013 257
Table 85: BI's NSCLC Portfolio Assessment, 2013 258
Table 86: BI SWOT Analysis, 2013 259
Table 87: Novartis NSCLC Portfolio Assessment, 2013 260
Table 88: Novartis SWOT Analysis, 2013 260
Table 89: Global Sales Forecasts ($m) for NSCLC, 2012-2022 263
Table 90: Global NSCLC Market - Drivers and Barriers, 2012-2022 265
Table 91: Sales Forecasts ($m) for NSCLC in the United States, 2012-2022 271
Table 92: Key Events Impacting Sales for NSCLC in the United States, 2012-2022 273
Table 93: NSCLC Market in the United States - Drivers and Barriers, 2012-2022 274
Table 94: Sales Forecasts ($m) for NSCLC in France, 2012-2022 279
Table 95: Key Events Impacting Sales for NSCLC in France, 2012-2022 281
Table 96: NSCLC Market in France - Drivers and Barriers, 2012-2022 282
Table 97: Sales Forecasts ($m) for NSCLC in Germany, 2012-2022 286
Table 98: Key Events Impacting Sales for NSCLC in Germany, 2012-2022 288
Table 99: NSCLC Market in Germany - Drivers and Barriers, 2012-2022 289
Table 100: Sales Forecasts ($m) for NSCLC in Italy, 2012-2022 293
Table 101: Key Events Impacting Sales for NSCLC in Italy, 2012-2022 295
Table 102: NSCLC Market in Italy - Drivers and Barriers, 2012-2022 295
Table 103: Sales Forecasts ($m) for NSCLC in Spain, 2012-2022 298
Table 104: Key Events Impacting Sales for NSCLC in Spain, 2012-2022 300
Table 105: NSCLC Market in Spain - Drivers and Barriers, 2012-2022 301
Table 106: Sales Forecasts ($m) for NSCLC in the UK, 2012-2022 304
Table 107: Key Events Impacting Sales for NSCLC in the UK, 2012-2022 306
Table 108: NSCLC Market in the United Kingdom - Drivers and Barriers, 2012-2022 307
Table 109: Sales Forecasts ($m) for NSCLC in Japan, 2012-2022 311
Table 110: Key Events Impacting Sales for NSCLC in Japan, 2012-2022 313
Table 111: NSCLC Market in Japan - Drivers and Barriers, 2012-2022 313
Table 112: Sales Forecasts ($m) for NSCLC in China, 2012-2022 318
Table 113: Key Events Impacting Sales for NSCLC in China, 2012-2022 320
Table 114: NSCLC Market in China - Drivers and Barriers, 2012-2022 320
Table 115: Sales Forecasts ($m) for NSCLC in India, 2012-2022 325
Table 116: Key Events Impacting Sales for NSCLC in India, 2012-2022 327
Table 117: NSCLC Market in India - Drivers and Barriers, 2012-2022 327
Table 118: Five-Year Prevalence of NSCLC 366
Table 119: Key Launch Dates 367
Table 120: Key Patent Expiries 368
Table 121: Physicians Surveyed by Country 385

List of Figures

Figure 1: 9MM, Age-Standardized (World) Lung Cancer Incidence, Men Ages ?40 Years, 1993-2002 39
Figure 2: 9MM, Age-Standardized (World) Lung Cancer Incidence, Women Ages ?40 Years, 1993-2002 39
Figure 3: Age-Standardized (US, 2000) Lung Cancer Incidence and Mortality, Men and Women, All Ages, US, 1999-2008 43
Figure 4: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ?40 Years, US, 1993-2008 44
Figure 5: Relative Risk of Death from Lung Cancer in Current Smokers, Men and Women, US 45
Figure 6: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ?40 Years, France, 1993-2008 47
Figure 7: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ?40 Years, Germany, 1993-2008 48
Figure 8: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ?40 Years, Italy, 1993-2008 50
Figure 9: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ?40 Years, Spain, 1991-2008 52
Figure 10: Age-Standardized (World) Lung Cancer Incidence and Mortality, Ages ?40 Years, UK, 1993-2008 53
Figure 11: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ?40 Years, Japan, 1993-2008 55
Figure 12: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ?40 Years, China, 1993-2008 57
Figure 13: Age-Standardized (World) Lung Cancer Incidence, Men and Women Ages ?40 Years, India, 1993-2002 59
Figure 14: 9MM, Incident Cases of NSCLC, Men and Women Ages ?40 Years, N, Selected Years 2012-2022 71
Figure 15: 9MM, Incident Cases of NSCLC, by Sex, Ages ?40 Years, N, 2012 75
Figure 16: 9MM, Age-Standardized (World) NSCLC Incidence, 2012 76
Figure 17: 9MM, Incident Cases of NSCLC, by Stage at Diagnosis, Men and Women Ages ?40 Years, % and N, 2012 79
Figure 18: 9MM, Incident Cases of NSCLC by Histological Subtype, Men and Women Ages ?40 Years, %, 2012 82
Figure 19: 9MM, Proportion of Smokers Among NSCLC Cases Ages >40 Years and the General Population, Men and Women, %, 2012 83
Figure 20: Smoking History in NSCLC Cases in the 9MM, Men and Women Ages ?40 Years, N, 2012 84
Figure 21: NSCLC Therapeutics - Clinical Trials by Country, 2013 166
Figure 22: Competitive Assessment of Late-Stage Pipeline Agents in NSCLC, 2012-2022 171
Figure 23: Company Portfolio Gap Analysis in NSCLC, 2012-2022 245
Figure 24: Global Sales for NSCLC by Region, 2012-2022 264
Figure 25: Sales for NSCLC in the US by Drug Class, 2012-2022 272
Figure 26: Sales for NSCLC in France by Drug Class, 2012-2022 280
Figure 27: Sales for NSCLC in Germany by Drug Class, 2012-2022 287
Figure 28: Sales for NSCLC in Italy by Drug Class, 2012-2022 294
Figure 29: Sales for NSCLC in Spain by Drug Class, 2012-2022 299
Figure 30: Sales for NSCLC in the UK by Drug Class, 2012-2022 305
Figure 31: Sales for NSCLC in Japan by Drug Class, 2012-2022 312
Figure 32: Sales for NSCLC in China by Drug Class, 2012-2022 319
Figure 33: Sales for NSCLC in India by Drug Class, 2012-2022 326